OSAKA - Japanese biotech firm Takara Bio Inc. will start producing messenger RNA vaccines on a contract basis possibly from next January, its officials said Thursday, in a move likely to help cut the country's reliance on imports for COVID-19 vaccines.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
